Amended Report of Foreign Issuer (6-k/a)
April 11 2017 - 9:52AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of April 2017
FRESENIUS MEDICAL CARE AG & Co. KGaA
(Translation of registrants name into English)
Else-Kröner Strasse 1
61346 Bad Homburg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
o
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o
No
x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82
This Form 6-K/A amends the Form 6-K furnished by Fresenius Medical Care AG & Co. KGaA (the Company) on March 30, 2017 to correct the amount of voting rights within the invitation for its 2017 Annual General Meeting (AGM) of Shareholders to be held May 11, 2017 as well as providing information for holders of American Depositary Receipts regarding the AGM. None of the other information has been amended.
On or about April 10, 2017 the Depositary for the American Depositary Receipts (ADRs) representing the Companys ordinary shares will distribute to ADR holders (a) the AGM agenda and invitation, (b) a voting instruction card for ADR holders and (c) the Report of the Companys Supervisory Board. The Company will also furnish to the ADR Depositary certain additional information (the Supplemental Information) that the Company has agreed to make available to its ADR holders pursuant to the Pooling Agreement among the Company, Fresenius Medical Care Management AG, the Companys general partner, Fresenius SE & Co. KGaA and the Companys independent directors designated in the Pooling Agreement. This additional information was provided on a Form 6-K furnished by the Company on March 30, 2017. The Supplemental Information, which is derived from the Companys 2016 Annual Report on Form 20-F, relates to (i) security ownership of certain beneficial owners of the Company; (ii) trading markets for the Companys securities, (iii) directors and senior management of the Company; (iv) compensation of the Companys management board and our supervisory board; (v) options to purchase the Companys securities, and (vi) material transactions between the Company and its subsidiaries and directors, officers and controlling persons of the Company. The Supplemental Information also includes information regarding the fees paid to and services performed by the Companys independent accounting firm. The Supplemental Information for ADR holders has also been posted on the Companys web site, www.freseniusmedicalcare.com, and will be provided to any holder of ADRs without charge upon request made to the Depositary. The Supplemental Information is also being furnished with this report. The Company will furnish the voting instruction card with a report on Form 6-K when they are distributed to ADR holders by the Depositary.
The Companys Annual Report on Form 20-F and the Companys 2016 Annual Report have each been posted on the Companys web site.
EXHIBITS
The following exhibits are being furnished with this Report:
Exhibit 99.1
English convenience translation of Agenda and corrected Invitation for the Annual General Meeting of Shareholders to be held May 11, 2017 published in the German electronic-
Bundesanzeiger
(Federal Gazette).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DATE: April 11, 2017
|
FRESENIUS MEDICAL CARE AG & Co. KGaA,
|
|
a partnership limited by shares, represented by:
|
|
|
|
FRESENIUS MEDICAL CARE MANAGEMENT AG, its
|
|
general partner
|
|
|
|
|
|
By:
|
/s/ RICE POWELL
|
|
|
Name:
|
Rice Powell
|
|
|
Title:
|
Chief Executive Officer and
|
|
|
|
Chairman of the Management Board of the General Partner
|
|
|
|
|
|
By:
|
/s/ MICHAEL BROSNAN
|
|
|
Name:
|
Michael Brosnan
|
|
|
Title:
|
Chief Financial Officer and
|
|
|
|
Member of the Management Board of the General Partner
|
3
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Apr 2023 to Apr 2024